Shots:
Novartis has entered into a definitive agreement with Synnovation to acquire Pikavation Therapeutics (Synnovation’s subsidiary) & its portfolio of PI3Kα inhibitor programs, incl. SNV4818, a P-I/II asset for HR+/HER2- metastatic breast cancer & other solid tumors
As per the deal, Synnovation will receive $2B upfront, & ~$1B in development, regulatory, & commercial milestones, representing…
